Valuation: Avalyn Pharma Inc.

Market Cap 1.22B 1.08B 1.01B 919M 1.73B 117B 1.75B 12.2B 4.73B 59.74B 4.56B 4.46B 192B P/E 2026 *
-8.79x
P/E 2027 * -9.31x
Enterprise Value 1.23B 1.09B 1.02B 931M 1.76B 118B 1.77B 12.36B 4.79B 60.55B 4.63B 4.53B 194B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
1 day+2.26%
1 week+0.16%
Current month-1.28%
1 month-20.95%
3 months-5.40%
1 week 26.57
Extreme 26.57
29
1 month 26.57
Extreme 26.57
38.7
Current year 24.15
Extreme 24.15
40.17
1 year 24.15
Extreme 24.15
40.17
3 years 24.15
Extreme 24.15
40.17
5 years 24.15
Extreme 24.15
40.17
10 years 24.15
Extreme 24.15
40.17
Manager TitleAgeSince
Chief Executive Officer 50 14/10/2022
Director of Finance/CFO 47 01/05/2024
Chief Tech/Sci/R&D Officer 60 01/08/2023
Director TitleAgeSince
Director/Board Member 51 01/03/2017
Director/Board Member 50 01/03/2017
Director/Board Member 50 -
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Free

Director

31,182 0.0703%
01/05/26
F-Prime, Inc.
ConversionCompany -727,585 1.4654%
01/05/26
SR One Capital Management LP
ConversionCompany 38,914,842 87.8200%
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%+0.16% - - 1.22B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.88%-4.49%+26.37%+33.19% 42.91B
-0.16%+0.63%+351.36%+688.19% 44.13B
-1.39%-1.99%+2.47%+98.14% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+1.72%-6.71%-28.06%+333.27% 23.71B
Average +0.04%-0.98%+52.26%+158.44% 39.37B
Weighted average by Cap. +0.05%-0.41%+57.36%+150.03%

Financials

2026 *2027 *
Net sales - -
Net income -124M -111M -103M -94.06M -177M -11.96B -179M -1.25B -484M -6.12B -467M -457M -19.63B -135M -120M -112M -102M -193M -13.02B -195M -1.36B -527M -6.66B -509M -498M -21.37B
Net Debt 16.4M 14.57M 13.6M 12.39M 23.37M 1.58B 23.59M 165M 63.76M 806M 61.56M 60.22M 2.59B -442M -393M -367M -334M -631M -42.53B -637M -4.44B -1.72B -21.74B -1.66B -1.62B -69.78B
Logo Avalyn Pharma Inc.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase 1b clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.
Employees
55
Date Price Change Volume
03/10/26 $28.13 +2.59% 526,198
01/10/26 $27.42 -3.76% 423,592
30/09/26 $28.49 +5.13% 347,615
29/09/26 $27.10 -4.31% 421,962
28/09/26 $28.32 +0.85% 205,865
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.42USD
Average target price
62.25USD
Spread / Average Target
+127.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVLN Stock